EGRX - EGRX FINAL DEADLINE ALERT: Hagens Berman National Trial Attorneys Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities Fraud Class Action | Benzinga

SAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantial losses to submit your losses now.

Class Period: Aug. 8, 2023 – Nov. 28, 2023
Lead Plaintiff Deadline: Feb. 9, 2024
Visit: www.hbsslaw.com/investor-fraud/EGRX
Contact An Attorney Now: EGRX@hbsslaw.com
                                                    844-916-0895

Eagle Pharmaceuticals, Inc. (EGRX) Securities Fraud Class Action:

On Jan. 15, 2024, Eagle announced that it had received a limited waiver from its lenders on the defaults and events of default that occurred as a result of the company's (i) impending restatement of Q-2 2023 financials and (ii) failure to timely deliver Q-3 2023 financial statements.

While Eagle's securing the lenders' limited waiver staves off a potential liquidity crisis, Eagle disclosed that until the Company satisfies its financial statement requirements its line of credit has been halved, reducing from $100 million to $50 million.

The line of credit reduction follows the filing of a securities fraud class action suit against Eagle and its executives challenging the company's admitted improper accounting.

The securities class action lawsuit alleges that Defendants misrepresented and failed to disclose that: (i) Eagle was experiencing ...

EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities Fraud Class Action>Full story available on Benzinga.com